14159 capital gp llc - through partnership investment history in Synageva biopharma corp

Filed on 2012-01-09 by 14159 Capital (Gp), Llc SEC CIK 1317493 Form 4

Accession 0001144204-12-001425.txt Sec File: edgar/data/1317493/0001144204-12-001425-index.htm

2012-01-05 14159 Capital Gp Llc (CIK 1317493) through Through Partnership

Invested in Synageva Biopharma Corp bought 29089 shares at $25.18 remaining shares owned 135739

Common Stock Synageva Biopharma Corp Geva Transaction code: A Grant, award, or other acquisition

f1 in addition to 14159 capital (gp), llc, this form 4 is being filed jointly by julian c. baker and felix j. baker, each of whom has the same business address as 14159 capital (gp), llc and may be deemed to have a pecuniary interest in securities owned by it. felix j. baker is a director of the issuer. because of certain relationships with other security holders of the issuer, the reporting persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (continued in footnote 2).
f2 however, the reporting persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of section 13(d)(3) of the securities exchange act of 1934, as amended, or rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
f3 represents securities owned directly by 14159, l.p., the sole general partner of which is 14159 capital, l.p., a limited partnership the sole general partner of which is 14159 capital (gp),llc. julian c. baker and felix j. baker are controlling members of 14159 capital (gp), llc. in addition, julian c. baker and felix j. baker may be deemed to beneficially own 143,462 shares of synageva held by fbb associates by virtue of the fact that each of julian c. baker and felix j. baker own a 50% interest in fbb associates.


Filed on 2011-11-04 by 14159 Capital (Gp), Llc SEC CIK 1317493 Form 4

Accession 0001144204-11-061504.txt Sec File: edgar/data/1317493/0001144204-11-061504-index.htm

2011-11-02 14159 Capital Gp Llc (CIK 1317493) through Through Partnership

Invested in Synageva Biopharma Corp bought 90457 shares remaining shares owned 106650

Common Stock Synageva Biopharma Corp Geva Transaction code: A Grant, award, or other acquisition

f1 in addition to 14159 capital (gp), llc, this form 4 is being filed jointly by julian c. baker and felix j. baker, each of whom has the same business address as 14159 capital (gp), llc and may be deemed to have a pecuniary interest in securities owned by it. felix j. baker is a director of the issuer. because of certain relationships with other security holders of the issuer, the reporting persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (continued in footnote 2).
f2 however, the reporting persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of section 13(d)(3) of the securities exchange act of 1934, as amended, or rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
f3 on november 2, 2011, tesla merger sub, inc., a wholly owned subsidiary of trimeris, inc. ("trimeris"), completed its merger (the "merger") with and into synageva biopharma corp. ("synageva"). in connection with the completion of the merger, trimeris changed its name from "trimeris, inc." to "synageva biopharma corp." and the stock of the combined company began trading on the nasdaq global market under the symbol "geva". on the effective date of the merger, the closing price of trimeris common stock was $3.07.
f7 received in exchange for 219,249 shares of synageva series d-2 preferred stock (on as as-converted to former synageva common stock basis) based on an exchange ratio of 0.413 in connection with the merger and after trimeris having effected a 1 for 5 reverse stock split.
f4 represents securities owned directly by 14159, l.p., the sole general partner of which is 14159 capital, l.p., a limited partnership the sole general partner of which is 14159 capital (gp),llc. julian c. baker and felix j. baker are controlling members of 14159 capital (gp), llc. in addition, julian c. baker and felix j. baker may be deemed to beneficially own 143,462 shares of synageva held by fbb associates by virtue of the fact that each of julian c. baker and felix j. baker own a 50% interest in fbb associates.


Filed on 2011-11-04 by 14159 Capital (Gp), Llc SEC CIK 1317493 Form 4

Accession 0001144204-11-061504.txt Sec File: edgar/data/1317493/0001144204-11-061504-index.htm

2011-11-02 14159 Capital Gp Llc (CIK 1317493) through Through Partnership

Invested in Synageva Biopharma Corp bought 8185 shares remaining shares owned 16193

Common Stock Synageva Biopharma Corp Geva Transaction code: A Grant, award, or other acquisition

f1 in addition to 14159 capital (gp), llc, this form 4 is being filed jointly by julian c. baker and felix j. baker, each of whom has the same business address as 14159 capital (gp), llc and may be deemed to have a pecuniary interest in securities owned by it. felix j. baker is a director of the issuer. because of certain relationships with other security holders of the issuer, the reporting persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (continued in footnote 2).
f2 however, the reporting persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of section 13(d)(3) of the securities exchange act of 1934, as amended, or rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
f3 on november 2, 2011, tesla merger sub, inc., a wholly owned subsidiary of trimeris, inc. ("trimeris"), completed its merger (the "merger") with and into synageva biopharma corp. ("synageva"). in connection with the completion of the merger, trimeris changed its name from "trimeris, inc." to "synageva biopharma corp." and the stock of the combined company began trading on the nasdaq global market under the symbol "geva". on the effective date of the merger, the closing price of trimeris common stock was $3.07.
f6 received in exchange for 19,840 shares of synageva series c-2 preferred stock (on as as-converted to former synageva common stock basis) based on an exchange ratio of 0.413 in connection with the merger and after trimeris having effected a 1 for 5 reverse stock split.
f4 represents securities owned directly by 14159, l.p., the sole general partner of which is 14159 capital, l.p., a limited partnership the sole general partner of which is 14159 capital (gp),llc. julian c. baker and felix j. baker are controlling members of 14159 capital (gp), llc. in addition, julian c. baker and felix j. baker may be deemed to beneficially own 143,462 shares of synageva held by fbb associates by virtue of the fact that each of julian c. baker and felix j. baker own a 50% interest in fbb associates.


Filed on 2011-11-04 by 14159 Capital (Gp), Llc SEC CIK 1317493 Form 4

Accession 0001144204-11-061504.txt Sec File: edgar/data/1317493/0001144204-11-061504-index.htm

2011-11-02 14159 Capital Gp Llc (CIK 1317493) through Through Partnership

Invested in Synageva Biopharma Corp bought 7932 shares remaining shares owned 8008

Common Stock Synageva Biopharma Corp Geva Transaction code: A Grant, award, or other acquisition

f1 in addition to 14159 capital (gp), llc, this form 4 is being filed jointly by julian c. baker and felix j. baker, each of whom has the same business address as 14159 capital (gp), llc and may be deemed to have a pecuniary interest in securities owned by it. felix j. baker is a director of the issuer. because of certain relationships with other security holders of the issuer, the reporting persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (continued in footnote 2).
f2 however, the reporting persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of section 13(d)(3) of the securities exchange act of 1934, as amended, or rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
f3 on november 2, 2011, tesla merger sub, inc., a wholly owned subsidiary of trimeris, inc. ("trimeris"), completed its merger (the "merger") with and into synageva biopharma corp. ("synageva"). in connection with the completion of the merger, trimeris changed its name from "trimeris, inc." to "synageva biopharma corp." and the stock of the combined company began trading on the nasdaq global market under the symbol "geva". on the effective date of the merger, the closing price of trimeris common stock was $3.07.
f5 received in exchange for 19,227 shares of synageva series b-2 preferred stock (on as as-converted to former synageva common stock basis) based on an exchange ratio of 0.413 in connection with the merger and after trimeris having effected a 1 for 5 reverse stock split.
f4 represents securities owned directly by 14159, l.p., the sole general partner of which is 14159 capital, l.p., a limited partnership the sole general partner of which is 14159 capital (gp),llc. julian c. baker and felix j. baker are controlling members of 14159 capital (gp), llc. in addition, julian c. baker and felix j. baker may be deemed to beneficially own 143,462 shares of synageva held by fbb associates by virtue of the fact that each of julian c. baker and felix j. baker own a 50% interest in fbb associates.